Display options
Cite
Schifilliti C, Cucinotta L, Fedele V, et al. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat. 2014;2014:849623doi: 10.1155/2014/849623.
Schifilliti, C., Cucinotta, L., Fedele, V., Ingegnosi, C., Luca, S., & Leotta, C. (2014). Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain research and treatment, 2014849623. https://doi.org/10.1155/2014/849623
Schifilliti, Chiara, et al. "Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients." Pain research and treatment vol. 2014 (2014): 849623. doi: https://doi.org/10.1155/2014/849623
Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat. 2014;2014:849623. doi: 10.1155/2014/849623. Epub 2014 Apr 02. PMID: 24804094; PMCID: PMC3996286.
Copy Download .nbib Format: NLM
Share it on

Pain Res Treat. 2014;2014:849623. doi: 10.1155/2014/849623. Epub 2014 Apr 02.

Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients.

Pain research and treatment

Chiara Schifilliti, Lelio Cucinotta, Viviana Fedele, Carmela Ingegnosi, Salvatore Luca, Carmelo Leotta

Affiliations

  1. Associazione MOV.I.S, Onlus di Giarre, Via Teatro 81, Giarre, 95014 Catania, Italy.

PMID: 24804094 PMCID: PMC3996286 DOI: 10.1155/2014/849623

Abstract

The present study evaluated the effectiveness of micronized palmitoylethanolamide (PEA-m) treatment in reducing the painful symptoms experienced by diabetic patients with peripheral neuropathy. PEA-m, a fatty acid amide of the N-acylethanolamine family, was administered (300 mg twice daily) to 30 diabetic patients suffering from painful diabetic neuropathy. Before treatment start, after 30 and 60 days the following parameters were assessed: painful symptoms of diabetic peripheral neuropathy using the Michigan Neuropathy Screening instrument; intensity of symptoms characteristic of diabetic neuropathic pain by the Total Symptom Score; and intensity of different subcategories of neuropathic pain by the Neuropathic Pain Symptoms Inventory. Hematological and blood chemistry tests to evaluate metabolic control and safety were also performed. Statistical analysis (ANOVA) indicated a highly significant reduction in pain severity (P < 0.0001) and related symptoms (P < 0.0001) evaluated by Michigan Neuropathy Screening instrument, Total Symptom Score, and Neuropathic Pain Symptoms Inventory. Hematological and urine analyses did not reveal any alterations associated with PEA-m treatment, and no serious adverse events were reported. These results suggest that PEA-m could be considered as a promising and well-tolerated new treatment for symptomatology experienced by diabetic patients suffering from peripheral neuropathy.

References

  1. Neuroscience. 2002;114(2):291-9 - PubMed
  2. Ther Adv Endocrinol Metab. 2011 Feb;2(1):27-38 - PubMed
  3. Life Sci. 2005 Aug 19;77(14):1685-98 - PubMed
  4. Diabetologia. 1995 Dec;38(12):1425-33 - PubMed
  5. Pain. 2012 Jan;153(1):33-41 - PubMed
  6. CNS Neurol Disord Drug Targets. 2011 Dec;10(8):916-20 - PubMed
  7. Pharmacol Res. 2010 Apr;61(4):321-8 - PubMed
  8. Pain Pract. 2010 May-Jun;10(3):167-84 - PubMed
  9. Inflammopharmacology. 2014 Apr;22(2):79-94 - PubMed
  10. Mol Pain. 2011 Jan 10;7:3 - PubMed
  11. CNS Neurol Disord Drug Targets. 2013 Feb 1;12(1):4-6 - PubMed
  12. Agents Actions. 1993;39 Spec No:C145-7 - PubMed
  13. Neuroscientist. 2010 Oct;16(5):519-31 - PubMed
  14. Pain Med. 2012 Sep;13(9):1121-30 - PubMed
  15. Br J Pharmacol. 2002 Jan;135(1):181-7 - PubMed
  16. Br J Pharmacol. 2002 Oct;137(4):413-20 - PubMed
  17. J Neuroendocrinol. 2011 Jul;23(7):591-600 - PubMed
  18. Diabetes Res Clin Pract. 1998 Mar;39(3):165-72 - PubMed
  19. J Pharmacol Exp Ther. 2006 Dec;319(3):1051-61 - PubMed
  20. Exp Diabesity Res. 2003 Oct-Dec;4(4):303-12 - PubMed
  21. Minerva Med. 2011 Apr;102(2):141-7 - PubMed
  22. Diabetes Care. 2009 Nov;32 Suppl 2:S414-9 - PubMed
  23. J Orofac Pain. 2012 Spring;26(2):99-104 - PubMed
  24. Neurol Sci. 2009 Apr;30(2):99-106 - PubMed
  25. Biochimie. 2010 Jun;92(6):724-7 - PubMed
  26. J Neurochem. 2010 Sep 1;114(5):1460-75 - PubMed
  27. Diabetes Care. 1994 Nov;17(11):1281-9 - PubMed
  28. Eur J Pharmacol. 1996 Apr 11;300(3):227-36 - PubMed
  29. Diabetes Care. 2010 Oct;33(10):2285-93 - PubMed
  30. Br J Pharmacol. 2013 Mar;168(6):1430-44 - PubMed
  31. Pain. 2008 Oct 31;139(3):541-550 - PubMed
  32. Postgrad Med. 2012 Jul;124(4):145-53 - PubMed
  33. J Neuroinflammation. 2013 Feb 01;10:20 - PubMed
  34. Pain Med. 2010 May;11(5):781-4 - PubMed
  35. J Neurosci. 2012 Sep 12;32(37):12735-43 - PubMed
  36. Pain. 2004 Apr;108(3):248-257 - PubMed
  37. Diabetes Metab Res Rev. 2012 Feb;28 Suppl 1:8-14 - PubMed

Publication Types